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Rat and human aortic smooth muscle cells display
differing migration and matrix metalloproteinase
activities in response to dexamethasone
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J. A. Freischlag, MD, A. E. Collins, PhD, R. E. Law, PhD, and H. A. Gelabert, MD, Los Angeles, Calif
Objective: The steroid dexamethasone inhibits neointimal hyperplasia development in rats but not in humans. This study
investigates the differential effects of dexamethasone on rat and human smooth muscle cell migration and matrix
metalloproteinase (MMP) activity.
Methods: Rat aortic smooth muscle cells were harvested from Sprague-Dawley rats. Human aortic smooth muscle cells
were obtained from Clonetics. Boyden chamber migration assays were performed with chemoattractant (platelet-derived
growth factor) and varying concentrations of dexamethasone (109 to 105 mol/L). Zymography of culture media was
used to assess MMP activity, and Western blot analysis was used for quantification of MMP-2 and tissue inhibitor of
MMP-2 (TIMP-2) secretion.
Results: Dexamethasone inhibits rat aortic smooth muscle cell migration in a dose-dependent fashion. An increase in
concentrations of dexamethasone does not effect human aortic smooth muscle cell migration. Rat aortic smooth muscle
cell MMP-2 activity is inhibited with dexamethasone in a dose-dependent fashion, and human aortic smooth muscle cell
MMP-2 activity is unchanged with dexamethasone. MMP-2 secretion is inhibited with dexamethasone in rat aortic
smooth muscle cells but remains unaltered in human aortic smooth muscle cells. Dexamethasone increases rat aortic
smooth muscle cell TIMP-2 secretion, and human aortic smooth muscle cell TIMP-2 secretion remains constant.
Conclusion: Dexamethasone inhibits rat aortic smooth muscle cell migration, MMP-2 activity, and MMP-2 secretion and
increases TIMP-2 secretion. These effects are not observed in human aortic smooth muscle cells. These findings may
explain why dexamethasone inhibits neointimal hyperplasia in animal models but is ineffective in humans. Inhibition of
human smooth muscle cell migration in vitro may be useful in predicting the effectiveness of future therapeutic agents for
treatment of neointimal hyperplasia in humans. (J Vasc Surg 2002;35:1253-9.)
After vascular interventions, restenosis remains a critical
clinical issue.1-4 Neointimal hyperplasia is a common com-
plication of most vascular interventions that causes stenosis
and occlusion of the vessel within the first 6 months.1
Although many pharmacologic treatments, including dexa-
methasone, have been successful in animal studies, none
have been successful in humans.
Neointimal lesion development is dependent on the
migration of smooth muscle–like cells to the neointima,
their proliferation, and their matrix secretion and deposi-
tion.5-7 Smooth muscle cell migration is critical in the
formation of neointima, early restenosis, vessel occlusion,
and thus, ultimate failure of vascular interventions.8
Vessel wall injury induces a variety of growth factors
and chemokines with smooth muscle cell migration. Mac-
rophages, endothelial cells, and platelets secrete chemoat-
tractants, such as platelet-derived growth factor (PDGF),
which then trigger smooth muscle migration.9 Activation
of smooth muscle cell migration and the steps by which
smooth muscle cells migrate remain poorly understood.10
Smooth muscle cell migration involves several pro-
cesses: chemoattractants induce migration, cells detach
from their environment, cells digest extracellular matrix, cells
translocate through the space created by the matrix digestion,
and cells reattach. Our laboratory has investigated the influ-
ence of extracellular matrix breakdown on migration.
Matrix metalloproteinases (MMPs) are zinc-dependent
proteolytic enzymes. MMPs include gelatinases, collag-
enases, and stromelysins. They degrade the extracellular
matrix during various cellular activities, including smooth
muscle cell migration. MMP-2 (gelatinase A) is involved in
smooth muscle cell migration11 and increases in animal
arterial balloon models.12 MMP-2 is secreted in the inac-
tive, zymogen, form and then activated with various other
proteins, including other MMPs and integrins. Matrix
breakdown in vivo is controlled with the balance between
MMPs and tissue inhibitors of MMPs (TIMPs), their nat-
ural inhibitors.13,14 TIMP-2 specifically inhibits MMP-2.
TIMPs inhibit neointimal hyperplasia formation in vivo and
smooth muscle cell migration in vitro.11,15
Multiple pharmacologic agents have been investigated
as potential prophylaxis and treatment for neointimal hy-
perplasia, including antihypertensive, antiplatelet, antilipid,
and antiinflammatory agents.16 Dexamethasone, a syn-
thetic glucocorticoid, has a wide variety of biologic actions,
including modulation and suppression of immune func-
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tion. Dexamethasone inhibits lymphocytes, fibroblasts, and
macrophages.17 Our laboratory has previously shown dexa-
methasone to inhibit neointimal hyperplasia development
after balloon injury in rat and rabbit models in vivo.18 We
have further shown dexamethasone to inhibit vascular
smooth muscle cell proliferation via inhibition of phos-
phorylation of the Rb-protein causing cell cycle arrest dur-
ing early G1 in both rat and human cells.19,20 However,
human glucocorticoid studies have been unsuccessful. The
M-HEART project showed in a large randomized clinical
trial that methylprednisone did not inhibit neointimal hy-
perplasia after balloon angioplasty.21
Glucocorticoids inhibit migration of multiple other cell
types.22,23 The effects of dexamethasone on smooth mus-
cle cell migration in humans and in animal models are not
clearly established and may account for the differential
effects on neointimal hyperplasia. We thus hypothesize that
dexamethasone has differential effects on rat and human
smooth muscle cell migration and that this is mediated
through MMP secretion and activity.
METHODS
Cell culture
Rat aortic smooth muscle cells. Rat aortic smooth
muscle cells were harvested as per Goetze et al.10 Briefly,
Sprague-Dawley rats (2 to 3 months old) were killed
with CO2. Thoracic aorta was harvested as described by
Chamley-Campbell, Campbell, and Ross.24 Endothelium
was removed mechanically, and the artery was minced and
placed on culture plates. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM), with 10% fetal bovine
serum (FBS), 1 mmol/L glutamine, 10 U/mL penicillin,
and 1 mg/ml streptomycin, at 37° C/5% CO2. Cells were
trypsin passaged after 10 days and then at 95% confluence.
Further studies were performed on cells at passage 4
through 6 and 60% to 90% confluence.
Typical hill-and-valley growth patterns and characteris-
tic cell morphology, and flow cytometry, established smooth
muscle cell purity. Flow cytometry of anti–smooth muscle
–actin antibody stained cells showed 95% 3% purity.
Human aortic smooth muscle cells. Human aortic
smooth muscle cells were obtained at passage 3 (Biowhit-
taker, Walkersville, Md). Human cells were maintained as
per Reil et al.19 In summary, cells were thawed according to
Biowhittaker protocol and maintained at 37° C/5% CO2 in
SmBM, with smooth muscle cell growth factors (Biowhit-
taker), 10% FBS, 10 U/mL penicillin, and 1 mg/mL
streptomycin. Cells were trypsin passaged at 95% conflu-
ence. Further studies were performed on cells at passage 4
through 6 and 60% to 90% confluence.
Migration assay
Migration was evaluated in a Boyden chamber after the
method of Goetze et al.10 Falcon (Sigma, St Louis, Mo)
filter wells were gelatin (0.25%) treated overnight and
placed in Falcon 24-well culture plates. Cells were
trypsinized and phosphate-buffered saline solution (PBS)
washed. Rat cells were resuspended in 0.4% FBS/DMEM
(at 5  105 cells/mL), and human cells were resuspended
in 0.4% FBS/SmBM (at 2.5 105 cells/mL). Six hundred
L of 0.4% FBS/media was added to the lower chamber
and 200 L of cell suspension was added to the upper
chamber (50,000 rat cells per well; 25,000 human cells per
well). Incubation at 37° C/5% CO2 for 1 hour allowed for
cell attachment. Cells were treated with dexamethasone
concentrations as follows: 109 mol/L, 108 mol/L,
107 mol/L, 106 mol/L, and 105 mol/L. Three con-
trols were performed: a negative control (0.4% FBS media),
a positive control (30 mol/L PD98059: a MAP kinase
inhibitor and therefore a known migration inhibitor), and a
baseline movement control (0.4% FBS media). Dexameth-
asone or control was added to both upper and lower
compartments. Cells were incubated at 37° C/5% CO2 for
30 minutes, and PDGF-BB (20 ng/mL) was added to the
lower compartment of each chamber. The baseline move-
ment control received 0.4% FBS/media instead of PDGF.
Migration was performed at 37° C/5% CO2 for 4 hours
(rat cells) or 3 hours (human cells). The membranes were
PBS washed, nonmigrated cells were manually removed
from the upper membrane surface, and migrated cells were
fixed and stained with the DADE Behring Inc (Newark,
Del) Quik-Diff stain set. Membranes were slide-mounted,
and cells were counted with 320 high-power field. Four
random areas of cells per membrane were counted and
averaged. The number of cells and migration times were
optimized for maximal cell migration with minimal cell
overlap of both rat and human cells. At concentrations and
migration times greater than those used for each cell line,
accurate cell counts were impossible because of cell overlap
and clustering. The difference in optimal times and cell
number are believed to be the result of the use of human
PDGF-BB as the chemoattractant in both models.
The baseline movement control was subtracted from
each sample to account for random movement. Migration was
evaluated as a percentage of the negative control. For each
concentration of dexamethasone and each control, n 9.
Apoptosis assay
Flow cytometry was performed to evaluate for apopto-
sis as a potential cause of the observed inhibition in smooth
muscle cell migration. Cells were treated with dexametha-
sone at concentrations of 109 mol/L, 108 mol/L, 107
mol/L, 106 mol/L, and 105 mol/L in 0.4% FBS media.
A negative control with 0.4% FBS/DMEM in place of
dexamethasone and a positive control with 105 mol/L
nifedipine were performed. Culture plates were incubated
at 37° C/5% CO2 for 30 minutes and 20 ng/mL PDGF
was added. Plates were further incubated for 6 hours to
allow for apoptosis. Smooth muscle cells were trypsinized,
PBS washed, and resuspended in 100 L annexin-V buffer.
Cells were treated with the BioSource International, Inc
(Camarillo, Calif) ApoTarget apoptosis kit (Annexin-V flu-
orescein isothiocyanate and propidium iodide) according
to the ApoTarget protocol. Flow cytometry on a Becton
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Dickinson (Franklin Lakes, NJ) FACScan analytic cytome-
ter was performed, and results were analyzed (n  3).
Matrix metalloproteinase analysis
Matrix metalloproteinase production. Cells were
trypsinized, PBS washed, and resuspended in media
(DMEM for rat cells and SmBM for human cells) without
FBS (1  105 cells/mL for rat cells and 5  104 cells/mL
for human cells). The differences in cell concentrations
between rat and human cells were performed to parallel the
migration experiments. Five hundred L of cell suspension
was added to each well of a Falcon 24-well culture plate
(50,000 rat cells per well; 25,000 human cells per well).
Incubation for 1 hour at 37° C/5% CO2 allowed for cell
attachment. Dexamethasone was added to each well (con-
centrations: 109 mol/L, 108 mol/L, 107 mol/L,
106 mol/L, and 105 mol/L). A control of no dexa-
methasone was performed. After 30 minutes incubation at
37° C/5% CO2, 20 ng/mL PDGF was added. Plates were
incubated for 24 hours.
Matrix metalloproteinase activity. After 24 hours of
incubation, media was removed for analysis of MMP activ-
ity. MMPs were separated with sodium dodecylsulfate–
polyacrylamide gel electrophoresis (10% polyacrylamide
gels with 1 mg/mL gelatin). Electrophoresis was main-
tained below 20 mA per gel to preserve activity. Gels were
washed with 2.5% Triton X100 solution for 1 hour and
then zinc-containing incubation buffer for 30 minutes.
After 24 hours at 37° C in zinc-containing incubation
buffer, gels were Coomassie blue stained according to
standard protocol. Light bands were compared with stan-
dard markers and identified with molecular weights (n 
3). Densitometry was performed with standard National
Institutes of Health densitometry software.
Matrix metalloproteinase and tissue inhibitor of
matrix metalloproteinase secretion. After 24 hours of
incubation, media was removed for further analysis. So-
dium dodecylsulfate–polyacrylamide electrophoresis (10%
polyacrylamide gel) was performed to separate proteins.
Immunoassay was performed according to the protocol of
Goetze et al.10 Protein samples separated with polyacryl-
amide gel electrophoresis were transferred to nitrocellulose
membranes with Bio-Rad (Hercules, Calif) transblotters.
Nonspecific protein binding was blocked with 5% fat free
milk and 0.1% Tween 20 in triethanolamine-buffered solu-
tion. The membranes were exposed to primary antibody,
Chemicon International (Temecula, Calif) mouse anti–
MMP-2 antibody, or Sigma rabbit anti–TIMP-2 antibody,
at 1:500 dilution in blocking buffer solution overnight at
4° C. Membranes were washed three times for 15 minutes
with 0.1% Tween 20 in triethanolamine-buffered solution.
The blots were exposed to secondary antibody, Sigma anti-
mouse, or antirabbit secondary antibody in blocking solution
at 1:1000 dilution for 1 hour. Blots were washed as previously
mentioned and analyzed with the Amersham Pharmacia Bio-
tech (Piscataway, NJ) ECL Western blotting detection system
(n 3). Densitometry was performed with standard National
Institutes of Health densitometry software.
Statistical analysis
All experiments were repeated multiple times (three
times of more). Analysis of variance was performed to
evaluate for significant differences between groups. Post
hoc comparisons with Student-Newman-Keuls tests were
performed. Results with a random probability of less than
.05 were considered significant.
RESULTS
Cell migration
Boyden Chamber assays were used to evaluate rat and
human aortic smooth muscle cell migration after dexa-
methasone treatment. Dexamethasone inhibited rat aortic
smooth muscle cell migration in a dose-dependent fashion
(Fig 1, A). Dexamethasone at 107, 106, and 105
mol/L reduced rat aortic smooth muscle cell migration to
Fig 1. Smooth muscle cell migration. Dexamethasone inhibits rat aortic smooth muscle cell migration in dose-
dependent fashion (n  9). Dexamethasone does not alter human aortic smooth muscle cell migration (n  9). *P 
.05.
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51%, 31%, and 17% of the control, respectively (P  .05).
Dexamethasone did not alter human aortic smooth muscle
cell migration (Fig 1, B).
Apoptosis
Flow cytometry assays were performed to detect the
presence of apoptotic and late apoptotic or dead cells with
Annexin-V fluorescein isothiocyanate and propidium io-
dide stains. When compared with controls, dexamethasone
did not cause early or late apoptosis of rat or human aortic
smooth muscle cells (Fig 2).
Matrix metalloproteinase–2 secretion
Western immunoblot testing was performed on rat
and human aortic smooth muscle cell secreted protein.
Dexamethasone inhibited rat aortic smooth muscle cell
MMP-2 secretion (Fig 3, A). Densitometric analysis
results (Fig 3, B) showed this to be dose-dependent and
statistically significant for concentrations of 106 mol/L
and greater (P .05). Western immunoblot testing results
of human smooth muscle cell secretion showed no change
in MMP-2 secretion with increasing doses of dexameth-
Fig 3. MMP-2 secretion. Dexamethasone inhibits rat aortic smooth muscle cell MMP-2 secretion in dose-dependent
manner (n 3). Top, Western blot immunoassay. Densitometry (below). Dexamethasone does not effect human aortic
smooth muscle cell MMP-2 secretion (n  3). Bottom, Western blot immunoassay. Densitometry (below). *P  .05.
Fig 2. Apoptosis. Dexamethasone at 109 mol/L to 105 mol/L does not induce apoptosis of rat or human smooth
muscle cells. Cell survival was uniform throughout all groups, as determined with flow cytometry (n  3).
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asone (Fig 3, C). This test was quantified with densitom-
etry (Fig 3, D).
Cell matrix metalloproteinase–2 activity
Zymography results showed that dexamethasone in-
hibited MMP-2 activity of rat aortic smooth muscle cells
(Fig 4, A). Densitometry (Fig 4, B) quantified this effect,
which was dose-dependent and statistically significant for
concentrations of 107 mol/L and greater (P  . 05).
Human aortic smooth muscle cell MMP-2 activity re-
mained stable in response to dexamethasone (Fig 4, C),
quantified with densitometry (Fig 4, D). No other secreted
MMPs, including MMP-9, were detectable with zymogra-
phy for either rat or human cells.
Tissue inhibitor of matrix metalloproteinase–2
secretion
Western immunoblot testing results showed that
dexamethasone increased rat aortic smooth muscle cell
secretion of TIMP-2 (Fig 5, A). Densitometry (Fig 5, B)
quantified this increase, which was dose-dependent and
statistically significant for concentrations of 109 mol/L
and greater (P  .05). Dexamethasone had no effect on
TIMP-2 secretion assayed via Western immunoblot test-
Fig 4. MMP-2 activity. Dexamethasone inhibits rat aortic smooth muscle cell MMP-2 activity in dose-dependent
manner (n  3). Top, Zymogram. Densitometry (below). Dexamethasone does not alter human aortic smooth muscle
cell MMP-2 activity (n  3). Bottom, Zymogram. Densitometry (below). *P  .05.
Fig 5. TIMP-2 secretion. Dexamethasone activates rat aortic smooth muscle cell TIMP-2 secretion in dose-
dependent manner (n  3). Top, Western blot immunoassay. Densitometry (below). Dexamethasone does not alter
TIMP-2 secretion (n  3). Bottom, Western blot immunoassay. Densitometry (below). *P  .05.
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ing (Fig 5, C). This was quantified with densitometry
(Fig 5, D).
DISCUSSION
Restenosis after angioplasty, surgery, and other vascu-
lar interventions remains a significant problem for the phy-
sician and patient.25 During the first 2 years after vascular
interventions, restenosis is caused by formation of neointi-
mal hyperplasia.26 Many pharmacologic agents have been
successful in prevention of neointimal hyperplasia in animal
models.27 Yet, in clinical human trials, they fail,28 showing
that different mechanisms govern human and animal mod-
els of neointimal hyperplasia.
Corticosteroids, including dexamethasone, have
shown differing results between animal18,29 and human
studies.21 Our previous investigations have shown that
dexamethasone inhibits rat and human vascular smooth
muscle cell proliferation via the same mechanism, namely,
inhibition of Rb-protein phosphorylation.20 The effect of
dexamethasone on smooth muscle cell migration remains a
possible explanation for the observed differences between
human and animal studies.
Smooth muscle cell migration is a complex event initi-
ated by various chemoattractants released in response to
vascular injury.8 Migration is dependent on MMP expres-
sion and activation. MMPs break down the extracellular
matrix, allowing smooth muscle cells to travel through the
internal elastic lamina to the subendothelial region of the
vessel wall.11 MMP-2 and MMP-9 digest the internal elas-
tic lamina,13 and after vascular injury, their expression is
increased.12 Inhibition of MMP-2 directly inhibits smooth
muscle cell migration.11
Inactive pro–MMP-2 is secreted by the smooth muscle
cell. Extracellularly, it is activated by one of several en-
zymes.4 Activated MMP-2 degrades extracellular matrix
proteins (including collagen, gelatin, elastin, fibronectin,
and proteoglycan core protein) and activates pro–MMP-9.
TIMPs inhibit MMP activity, and TIMP-2 specifically in-
hibits MMP-2. The balance between MMPs and TIMPs
regulates extracellular matrix breakdown and thus smooth
muscle cell migration.30
A longstanding assumption governing research in cell
biology is that homologous cells behave in similar manner
and may be substituted for each other in research studies. In
this experiment, we compare the effect of dexamethasone
on rat and human aortic smooth muscle cells. Our experi-
mental protocol uses different media for rat and human cell
lines because no single media would adequately sustain
both rat and human cells lines. The MMP assays are per-
formed at a longer time point than the migration assays,
which was necessary to acquire adequate amounts of MMPs
for assay. Fundamental differences between these cell lines
necessitated such minor modification of experimental pa-
rameters. Despite these differences, the study groups are as
similar as possible to facilitate the comparisons.
We evaluate dexamethasone’s actions on smooth mus-
cle cell MMP-2 and TIMP-2 as they relate to smooth
muscle cell migration. Dexamethasone inhibited rat aortic
smooth muscle cell migration, MMP-2 activity, and
MMP-2 secretion and increased TIMP-2 secretion. Thus,
in rat cells, dexamethasone negatively regulates MMP-2
activity with two distinct mechanisms, decreased MMP and
increased TIMP secretion. These effects are not observed
on human aortic smooth muscle cells. Dexamethasone
does not alter human smooth muscle cell migration,
MMP-2 secretion, MMP-2 activity, or TIMP-2 secretion.
This supports the hypothesis that dexamethasone inhibits
neointimal hyperplasia via MMP activity modulation and
thus inhibits smooth muscle cell migration in animal mod-
els. In humans, dexamethasone does not alter MMP activ-
ity or smooth muscle cell migration, and thus, neointimal
hyperplasia is not inhibited.
One potential explanation for the observed activity of
dexamethasone in inhibiting rat aortic smooth muscle cell
migration or the difference observed in human cells is that
it may be inducing apoptosis. Dexamethasone has been
linked to apoptosis of many cells and has been identified as
both a proapoptotic and antiapoptotic agent.31,32 To an-
swer this question, flow cytometry was used to assay for
apoptotic markers. With this method, we verified that
dexamethasone does not induce apoptosis of rat or human
aortic smooth muscle cells.
The differential action of dexamethasone on rat and
human smooth muscle cell MMP activity and migration has
not previously been investigated. Dexamethasone has dif-
ferent effects on rat and human MMP activity, which may
lead to the observed difference in action on smooth muscle
cell migration and ultimately the difference in neointimal
hyperplasia development. These observations suggest a key
difference in the mechanisms leading to MMP and TIMP
secretion by rat and human smooth muscle cells. This
differential mechanism also may be the mechanism by
which other trial drugs have failed in prevention of human
neointimal hyperplasia. Thus, assays of smooth muscle cell
migration may be a useful tool in predicting the effective-
ness of future therapeutic agents for the treatment of neo-
intimal hyperplasia in humans.
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